ARS Pharmaceuticals, Inc.(SPRY)Earnings, Financials & Key RatiosARS Pharmaceuticals, Inc. (SPRY) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's liquidity buffer has contracted to $24.3 million against a quarterly operating loss of $60.1 million, indicating an imminent risk of further capital dilution.
ARS Pharmaceuticals, Inc. (SPRY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
ARS Pharmaceuticals, Inc. (SPRY) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.61vs $0.53-15.1% | $23Mvs $22M+2.2% |
| Q2 2026 | Mar 9, 2026 | $0.42vs $0.42+0.0% | $28Mvs $26M+9.7% |
| Q4 2025 | Nov 10, 2025 | $0.52vs $0.45-15.6% | $33Mvs $26M+27.0% |
| Q3 2025 | Aug 13, 2025 | $0.46vs $0.41-12.2% | $16Mvs $28M-43.2% |
Recent stock market news and headlines for ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on Wednesday reaffirmed its expectation to achieve cash-flow breakeven in 2027, even as no additional commercial formulary decisions for its epinephrine nasal spray Neffy were secured during the July 1, 2026 coverage cycle.
ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary.
No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion
Key metrics vs top competitors for ARS Pharmaceuticals, Inc. (SPRY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.33 | $827.2M | -4.79 | -5.46% | -203.25% | -92.33% | — | |
| $9.16 | $2.12B | 15.27 | 19.63% | 32.43% | 38.97% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $283.80 | $40.64B | -186.71 | 35.9% | -9.05% | -15.13% | — | |
| $4.38 | $510.37M | -0.13 | 4.84% | -252.55% | -136.55% | — | |
| $80.78 | $9.58B | 31.55 | 37.55% | 23.13% | 126.27% | — |
ARS Pharmaceuticals, Inc. (SPRY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARS Pharmaceuticals, Inc. (SPRY) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 15, 2026·SEC
May 13, 2026·SEC
Mar 9, 2026·SEC
Get notified when SPRY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ARS Pharmaceuticals, Inc. (SPRY) stock FAQ — growth, dividends, profitability & financials explained
ARS Pharmaceuticals, Inc. (SPRY) reported $99.0M in revenue for fiscal year 2025.
ARS Pharmaceuticals, Inc. (SPRY) saw revenue decline by 5.5% over the past year.
ARS Pharmaceuticals, Inc. (SPRY) reported a net loss of $198.0M for fiscal year 2025.
ARS Pharmaceuticals, Inc. (SPRY) has a return on equity (ROE) of -92.3%. Negative ROE indicates the company is unprofitable.
ARS Pharmaceuticals, Inc. (SPRY) had negative free cash flow of $175.3M in fiscal year 2025, likely due to heavy capital investments.
